Inozyme Pharma Raises $67 Million in Series A2 Financing to Develop Therapies for Rare Mineralization Disorders – Financing to Advance Lead Development Program, INZ-701, through Clinical Proof of Concept in Two Indications – – Company Expands Pipeline with New Program for a Rare Mineralization Disorder – BOSTON, April 10, 2019-- Inozyme Pharma, Inc., a biotechnology company developing novel medicines to treat rare, debilitating, and life-threatening mineralization disorders, today announced that the Company raised $67 million in a Series A2 financing led by Pivotal bioVenture Partners and Sofinnova Investments.